Fonte: Blood. Nome do evento: The 66th ASH Annual Meeting Abstracts. Unidades: FMRP, ICB
Assuntos: FARMACOLOGIA, DOENÇAS SANGUÍNEAS E LINFÁTICAS, MEDULA ÓSSEA, CÉLULAS SANGUÍNEAS, MUTAÇÃO GENÉTICA, CITOMETRIA DE FLUXO, CAMUNDONGOS, CÉLULAS MIELOIDES, LEUCEMIA MIELOIDE, NEOPLASIAS POR TIPO HISTOLÓGICO
ABNT
PEREIRA-MARTINS, Diego Antonio et al. Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms. Blood, v. 144, p. 4518-4519, 2025Tradução . . Disponível em: https://doi.org/10.1182/blood-2024-209823. Acesso em: 08 out. 2025.APA
Pereira-Martins, D. A., Alves-Silva, A. B., Melo, M. A. de, Fonseca, N. P., Weinhäuser, I., Perez, F. A. B., et al. (2025). Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms. Blood, 144, 4518-4519. doi:10.1182/blood-2024-209823NLM
Pereira-Martins DA, Alves-Silva AB, Melo MA de, Fonseca NP, Weinhäuser I, Perez FAB, Bellomi ABR, Figueiredo-Pontes LL, Quek L, Chatzikyriakou P, Huls GA, Ammatuna E, Schuringa JJ, Traina F, Machado Neto JA. Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms [Internet]. Blood. 2025 ; 144 4518-4519.[citado 2025 out. 08 ] Available from: https://doi.org/10.1182/blood-2024-209823Vancouver
Pereira-Martins DA, Alves-Silva AB, Melo MA de, Fonseca NP, Weinhäuser I, Perez FAB, Bellomi ABR, Figueiredo-Pontes LL, Quek L, Chatzikyriakou P, Huls GA, Ammatuna E, Schuringa JJ, Traina F, Machado Neto JA. Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms [Internet]. Blood. 2025 ; 144 4518-4519.[citado 2025 out. 08 ] Available from: https://doi.org/10.1182/blood-2024-209823